(Q42252182)
Statements
1 reference
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy (English)
1 reference
Crystal Watson
1 reference
Anna Walker
1 reference
Stamatia T Alexopoulos
1 reference
Baris Deniz
1 reference
Ryan Arnold
1 reference
David Bates
1 reference
5 December 2013
1 reference
1 reference
30
1 reference
4
1 reference
629-635
1 reference
Identifiers
1 reference
1 reference